GWPH GW Pharmaceuticals Plc

+1.27  (+1%)
Previous Close 152.92
Open 154.1
Price To Book 6.53
Market Cap 4,762,270,092
Shares 30,885,726
Volume 275,796
Short Ratio
Av. Daily Volume 403,704

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released February 7, 2017.
Tetrahydrocannabinol (THC) and cannabidiol (CBD)
Glioblastoma Multiform- cancer
Phase 2 open-label trial to commence 1Q 2019.
GWP42006 (CBDV)
Rett syndrome
Phase 3 initiated December 2016. Part A nearing completion, unlikely to continue through to Part B.
Infantile spasms (IS)
Phase 2 trial did not meet endpoint
Type 2 diabetes
Phase 3 trials failed. Evaluating whether there are any next steps
Cancer pain
Phase 2 data released February 21, 2018 - primary endpoint not met.
GWP42006 (CBDV)
Phase 2 data released September 2015. Currently evaluating next steps
Approval announced June 25, 2018.
Dravet Syndrome and Lennox-Gastaut syndrome
sNDA filing due 4Q 2019.
Tuberous Sclerosis Complex
Phase 3 trial planned for 4Q 2019.
Spasticity due multiple sclerosis
GWP42006 (CBDV)
Phase 3 trial has commenced - May 6, 2019.
Rett syndrome
Phase 3 data to be presented at AAN May 7, 2019.
Epidiolex GWPCARE2
Dravet Syndrome

Latest News

  1. Better Buy: GW Pharmaceuticals vs. Amarin
  2. Early Success Of CBD Drug Looms Large For The Industry's Future
  3. GW Pharmaceuticals, NetApp, KB Home, PulteGroup, M/I Homes, Lennar and Toll Brothers highlighted as Zacks Bull and Bear of the Day
  4. Bull of the Day: GW Pharmaceuticals (GWPH)
  5. HubSpot, Kraft Heinz, CNBS, Canopy Growth, Aurora Cannabis and GW Pharmaceuticals highlighted as Zacks Bull and Bear of the Day
  6. Market Takes Off After Tariffs Pushed Back
  7. 3 Cannabis Stocks With the Fastest-Growing Sales
  8. Tilray to Report Earnings Today: Will It Top or Flop?
  9. Cannabis Expert Tim Seymour's Favorite Pot Stocks and ETF
  10. Weekly Cannabis Stock News: GW Pharmaceuticals Blows Past Estimates
  11. The Week In Cannabis: CannTrust Rallies Unexpectedly, Josh Kushner And Shane Victorino Join The Industry, And More
  12. Marijuana-derived epilepsy drug doubles sales, sending GW Pharma stock soaring
  13. Edited Transcript of GWPH.O earnings conference call or presentation 6-Aug-19 8:30pm GMT
  14. GW Pharmaceuticals (GWPH) Q2 2019 Earnings Call Transcript
  15. Cronos Group's Q2 Trounces Estimates
  16. Cramer: Epidiolex Maker GW Pharma Is Far From A 'Sketchy' Weed Business
  17. 6 Positive Catalysts to Drive GW Pharmaceuticals (GWPH) Stock Further
  18. The Rally in GW Pharmaceuticals Should Continue - Here's How I'd Play It
  19. 3 Pot Stocks With Rising Profit Projections
  20. GW Pharma Analysts Raise Estimates After CBD Drug Epidiolex Shows Strong Uptake